EVRYSDI

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
EVRYSDI
Generic name
RISDIPLAM
Manufacturer
Genentech, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
eceb9a99-7191-4be5-87c3-0102707cf98e
SPL ID
4f458301-5ac6-45ff-b913-5e0a6b3091f4
Version
28
Effective date
2026-11-02
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:49
Harmonized routes table
Harmonized routes
ORAL

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions in later-onset SMA (incidence at least 10% of patients treated with EVRYSDI and more frequent than control) were fever, diarrhea, and rash. ( 6.1 ) The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients. Additionally, adverse reactions with an incidence of at least 10% were upper respiratory tract infection, lower respiratory tract infection, constipation, vomiting, and cough. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials including patients with infantile-onset SMA, later-onset SMA, and pre-symptomatic SMA, a total of 491 patients (51% female, 74% Caucasian) were exposed to EVRYSDI for up to a median duration of 48.1 months (range: 0.6 to 63.4 months), with 231 patients receiving treatment for more than 24 months. At the time of first EVRYSDI dose, 90 (18%) patients were 18 years and older, 119 (24%) were 12 years to less than 18 years, 189 (39%) were 2 years to less than 12 years, 67 (14%) 2 months to less than 2 years, and 26 (5%) were less than 2 months. Additionally, safety was evaluated in 11 neonates with SMA aged less than 20 days at first dose (55% female, 73% not Hispanic or Latino) who were exposed to EVRYSDI for up to a median duration of 26 days (range: 7 to 29 days), including 3 patients less than 7 days of age who had a median duration of exposure of 8 days (range: 7 to 10 days). Clinical Trial in Later-Onset SMA The safety of EVRYSDI for later-onset SMA is based on data from a randomized, double-blinded, placebo-controlled study (Study 2 Part 2) in patients with SMA Type 2 or 3 (n = 180) [see Clinical Studies (14.2) ]. The patient population in Study 2 Part 2 ranged in age from 2 to 25 years at the time of the first dose. The most common adverse reactions (reported in at least 10% of patients treated with EVRYSDI and at an incidence greater than on placebo) in Study 2 Part 2 were fever, diarrhea, and rash. Table 2 lists the adverse reactions that occurred in at least 5% of patients treated with EVRYSDI and at an incidence ≥ 5% greater than on placebo in Study 2 Part 2. Table 2 Adverse Reactions Reported in ≥ 5% of Patients Treated with EVRYSDI and with an Incidence ≥ 5% Greater Than on Placebo in Study 2 Part 2 Adverse Reaction EVRYSDI (N = 120) % Placebo (N = 60) % Fever Includes pyrexia and hyperpyrexia. 22 17 Diarrhea 17 8 Rash Includes rash, erythema, rash maculo-papular, rash erythematous, rash papular, dermatitis allergic, and folliculitis. 17 2 Mouth and aphthous ulcers 7 0 Arthralgia 5 0 Urinary tract infection Includes urinary tract infection and cystitis. 5 0 Clinical Trial in Infantile-Onset SMA The safety of EVRYSDI therapy for infantile-onset SMA is based on data from an open-label study in 62 patients (Study 1) [see Clinical Studies (14.1) ]. The patient population ranged in age from 2 to 7 months at the time of the first EVRYSDI dose (weight range: 4.1 to 10.6 kg). The most frequent adverse reactions reported in infantile-onset SMA patients treated with EVRYSDI in Study 1 were similar to those observed in later-onset SMA patients in Study 2. Additionally, the following adverse reactions reported in ≥ 10% of patients were: upper respiratory tract infection (including nasopharyngitis, rhinitis), lower respiratory tract infection (including pneumonia, bronchitis), constipation, vomiting, and cough. Clinical Trials in Pre-Symptomatic and Neonatal Patients with SMA The safety of EVRYSDI therapy for pre-symptomatic SMA is based on data from an open-label, single-arm study in 26 patients (Study 3) [see Clinical Studies (14.3) ] . The patient population ranged in age from 16 to 41 days at the time of the first dose (weight range: 3.1 to 5.7 kg). The safety of EVRYSDI in pediatric patients with SMA who were less than 20 days of age at first dose is based on data from an open-label, single-arm study in 11 patients (Study 4) [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3) ]. The safety profile of EVRYSDI in Study 3 and Study 4 is consistent with the safety profile for SMA patients treated with EVRYSDI in other clinical trials. 6.2 Postmarketing Experience The following adverse reaction has been identified during post approval use of EVRYSDI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous disorders: Cutaneous vasculitis (Symptoms recovered after permanent discontinuation of EVRYSDI.)

adverse reactions table

<table width="80%" ID="t2"> <caption>Table 2 Adverse Reactions Reported in &#x2265; 5% of Patients Treated with EVRYSDI and with an Incidence &#x2265; 5% Greater Than on Placebo in Study 2 Part 2</caption> <col width="33%" align="left" valign="middle"/> <col width="34%" align="center" valign="middle"/> <col width="33%" align="center" valign="middle"/> <thead> <tr> <th align="center" styleCode="Lrule Rrule">Adverse Reaction</th> <th styleCode="Rrule">EVRYSDI (N = 120) %</th> <th styleCode="Rrule">Placebo (N = 60) %</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Fever<footnote>Includes pyrexia and hyperpyrexia.</footnote> </td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">17</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Diarrhea</td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">8</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Rash<footnote>Includes rash, erythema, rash maculo-papular, rash erythematous, rash papular, dermatitis allergic, and folliculitis.</footnote> </td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Mouth and aphthous ulcers</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Arthralgia</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr> <td styleCode="Lrule Rrule">Urinary tract infection<footnote>Includes urinary tract infection and cystitis.</footnote> </td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.